

Oncology Today with Dr Neil Love: ER-Positive Metastatic Breast Cancer (Interview Audio)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following categories best characterizes the mechanism of action of ipatasertib?
 - a. AKT inhibitor
 - b. Aromatase inhibitor
 - c. Bcl-2 inhibitor
 - d. CDK4/6 inhibitor
2. Which CDK4/6 inhibitor requires an electrocardiogram to be conducted before the initiation of treatment?
 - a. Palbociclib
 - b. Ribociclib
 - c. Abemaciclib
3. Alpelisib with fulvestrant has demonstrated clinical benefit for which patients with ER-positive metastatic breast cancer?
 - a. Only those with PI3K mutations
 - b. Those with and without PI3K mutations
4. Which of the following is the molecular target of SERDs (selective estrogen receptor degraders)?
 - a. Wild-type ER
 - b. ER with ESR-1 mutation
 - c. Both a and b